Literature DB >> 25701633

Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin.

Kwok-Ho Lam1, Guorui Yao1, Rongsheng Jin2.   

Abstract

Botulinum neurotoxins (BoNTs) are among the most deadly toxins known. They act rapidly in a highly specific manner to block neurotransmitter release by cleaving the soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) complex at neuromuscular junctions. The extreme toxicity of BoNTs relies predominantly on their neurotropism that is accomplished by recognition of two host receptors, a polysialo-ganglioside and in the majority of cases a synaptic vesicle protein, through their receptor-binding domains. Two proteins, synaptotagmin and synaptic vesicle glycoprotein 2, have been identified as the receptors for various serotypes of BoNTs. Here, we review recent breakthroughs in the structural studies of BoNT-protein receptor recognitions that highlight a range of diverse mechanisms by which BoNTs manipulate host neuronal proteins for highly specific uptake at neuromuscular junctions.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botulinum neurotoxin; Botulism; Host-pathogen recognition; Protein complex; Synaptic vesicle glycoprotein 2; Synaptotagmin

Mesh:

Substances:

Year:  2015        PMID: 25701633      PMCID: PMC4417461          DOI: 10.1016/j.pbiomolbio.2015.02.004

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  51 in total

1.  Structural analysis of botulinum neurotoxin type G receptor binding .

Authors:  John Schmitt; Andrew Karalewitz; Desirée A Benefield; Darren J Mushrush; Rory N Pruitt; Benjamin W Spiller; Joseph T Barbieri; D Borden Lacy
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

2.  Botulinum neurotoxin is shielded by NTNHA in an interlocked complex.

Authors:  Shenyan Gu; Sophie Rumpel; Jie Zhou; Jasmin Strotmeier; Hans Bigalke; Kay Perry; Charles B Shoemaker; Andreas Rummel; Rongsheng Jin
Journal:  Science       Date:  2012-02-24       Impact factor: 47.728

3.  Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity.

Authors:  Jasmin Strotmeier; Gesche Willjes; Thomas Binz; Andreas Rummel
Journal:  FEBS Lett       Date:  2012-01-16       Impact factor: 4.124

4.  Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.

Authors:  Andrew P-A Karalewitz; Zhuji Fu; Michael R Baldwin; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

Review 5.  Assembly and function of the botulinum neurotoxin progenitor complex.

Authors:  Shenyan Gu; Rongsheng Jin
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

6.  Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.

Authors:  Lisheng Peng; Ronnie P-A Berntsson; William H Tepp; Rose M Pitkin; Eric A Johnson; Pål Stenmark; Min Dong
Journal:  J Cell Sci       Date:  2012-03-27       Impact factor: 5.285

7.  The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites.

Authors:  Jasmin Strotmeier; Shenyan Gu; Stephan Jutzi; Stefan Mahrhold; Jie Zhou; Andreas Pich; Timo Eichner; Hans Bigalke; Andreas Rummel; Rongsheng Jin; Thomas Binz
Journal:  Mol Microbiol       Date:  2011-06-02       Impact factor: 3.501

8.  Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.

Authors:  Andreas Rummel; Kirstin Häfner; Stefan Mahrhold; Natallia Darashchonak; Matthew Holt; Reinhard Jahn; Silke Beermann; Tino Karnath; Hans Bigalke; Thomas Binz
Journal:  J Neurochem       Date:  2009-07-23       Impact factor: 5.372

9.  Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding.

Authors:  Pål Stenmark; Min Dong; Jérôme Dupuy; Edwin R Chapman; Raymond C Stevens
Journal:  J Mol Biol       Date:  2010-02-26       Impact factor: 5.469

10.  Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Authors:  Lisheng Peng; William H Tepp; Eric A Johnson; Min Dong
Journal:  PLoS Pathog       Date:  2011-03-31       Impact factor: 6.823

View more
  16 in total

1.  Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS).

Authors:  Farbod Torkamand; Seyed Javad Mirjavadi; Fatemeh Khatami; Fateme Guitynavard; Seyed Mohammad Kazem Aghamir
Journal:  Am J Clin Exp Urol       Date:  2019-10-25

Review 2.  Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis.

Authors:  Xing-Peng Di; De-Yi Luo; Xi Jin; Wan-Yu Zhao; Hong Li; Kun-Jie Wang
Journal:  Int Urogynecol J       Date:  2021-02-27       Impact factor: 2.894

3.  Molecular landscape of BoNT/B bound to a membrane-inserted synaptotagmin/ganglioside complex.

Authors:  Jorge Ramirez-Franco; Fodil Azzaz; Marion Sangiardi; Géraldine Ferracci; Fahamoe Youssouf; Michel Robert Popoff; Michael Seagar; Christian Lévêque; Jacques Fantini; Oussama El Far
Journal:  Cell Mol Life Sci       Date:  2022-08-25       Impact factor: 9.207

4.  Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.

Authors:  C Bandala; A L Cortés-Algara; C M Mejía-Barradas; I Ilizaliturri-Flores; R Dominguez-Rubio; C I Bazán-Méndez; E Floriano-Sánchez; J P Luna-Arias; M Anaya-Ruiz; E Lara-Padilla
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 5.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

6.  A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.

Authors:  Guorui Yao; Kwok-Ho Lam; Jasmin Weisemann; Lisheng Peng; Nadja Krez; Kay Perry; Charles B Shoemaker; Min Dong; Andreas Rummel; Rongsheng Jin
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

7.  Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies.

Authors:  Jacquie Maignel-Ludop; Marion Huchet; Johannes Krupp
Journal:  Pharmacol Res Perspect       Date:  2017-01-31

Review 8.  Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis.

Authors:  Bin Chiu; Huai-Ching Tai; Shiu-Dong Chung; Lori A Birder
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

Review 9.  Botulinum Toxin A for Controlling Obesity.

Authors:  Raffaela Pero; Lorena Coretti; Francesca Lembo
Journal:  Toxins (Basel)       Date:  2016-09-26       Impact factor: 4.546

Review 10.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.